MBX Biosciences to Present at Jefferies Global Healthcare Conference

MBX Biosciences, a clinical-stage biopharmaceutical company, announced that its President and CEO, Kent Hawryluk, and Chief Medical Officer, Sam Azoulay, M.D., will present at the Jefferies 2026 Global Healthcare Conference on June 3, 2026. The presentation will take place from 8:10 a.m. to 8:40 a.m. ET and will be accessible via a live webcast on the company's investor relations website, with a replay available for approximately 90 days. The company will provide updates on its pipeline, including canvuparatide (MBX 2109) for chronic hypoparathyroidism, which is preparing for Phase 3 development, and its obesity portfolio candidates, MBX 4291 in Phase 1 and MBX 5765 in preclinical development.